581 related articles for article (PubMed ID: 24409943)
1. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
2. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
3. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
4. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
[No Abstract] [Full Text] [Related]
6. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine treatment for Graves' hyperthyroidism: incidence of Graves orbitopathy.
Quah NQX; Sobti MM; Wren AM; Scawn R; Kalogianni E; Cleland J; Maenhout A
Nucl Med Commun; 2024 Feb; 45(2):103-107. PubMed ID: 37982569
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
10. Association between radioiodine therapy for Graves' hyperthyroidism and thyroid-associated ophthalmopathy.
El-Kaissi S; Bowden J; Henry MJ; Yeo M; Champion BL; Brotchie P; Nicholson GC; Wall JR
Int Ophthalmol; 2010 Aug; 30(4):397-405. PubMed ID: 20405165
[TBL] [Abstract][Full Text] [Related]
11. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis.
Vannucchi G; Campi I; Covelli D; Dazzi D; Currò N; Simonetta S; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3381-6. PubMed ID: 19567525
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy versus antithyroid medications for Graves' disease.
Ma C; Xie J; Wang H; Li J; Chen S
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
14. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole.
Kung AW; Yau CC; Cheng A
J Clin Endocrinol Metab; 1994 Aug; 79(2):542-6. PubMed ID: 7913934
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
17. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.
De Bellis A; Conzo G; Cennamo G; Pane E; Bellastella G; Colella C; Iacovo AD; Paglionico VA; Sinisi AA; Wall JR; Bizzarro A; Bellastella A
Endocrine; 2012 Apr; 41(2):320-6. PubMed ID: 22169963
[TBL] [Abstract][Full Text] [Related]
18. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
19. Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys-Waligórska A; Gołkowski F; Kusnierz-Cabala B; Buziak-Bereza M; Hubalewska-Dydejczyk A
Endokrynol Pol; 2011; 62(3):214-9. PubMed ID: 21717402
[TBL] [Abstract][Full Text] [Related]
20. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study.
Lai A; Sassi L; Compri E; Marino F; Sivelli P; Piantanida E; Tanda ML; Bartalena L
J Clin Endocrinol Metab; 2010 Mar; 95(3):1333-7. PubMed ID: 20061414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]